Anna Maria Calcagno

Anna Maria Calcagno

Auto-generated profile, based on publicly available information

Anna Maria Calcagno

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2007 in Science
Verified
Journal Article
Open access
PDF file
CKChava Kimchi-Sarfaty
Chava Kimchi-Sarfaty
JOJung Mi Oh
Jung Mi Oh
IKIn-Wha Kim
In-Wha Kim
ZSZuben E. Sauna
Zuben E. Sauna
ACAnna Maria Calcagno
Anna Maria Calcagno
MGMichael M. Gottesman
Michael M. Gottesman
Synonymous single-nucleotide polymorphisms (SNPs) do not produce altered coding sequences, and therefore they are not expected to change the function of the protein in which they occur. We report that a synonymous SNP in the Multidrug Resistance 1 ( MDR 1) gene, part of a haplotype previously linked to altered function of the MDR 1 gene product P-glycoprotein (P-gp), nonetheless results in P-gp with altered drug and inhibitor interactions. Similar mRNA and protein levels, but altered conformations, were found for wild-type and polymorphic P-gp. We hypothesize that the presence of a rare codon, marked by the synonymous polymorphism, affects the timing of cotranslational folding and insertion of P-gp into the membrane, thereby altering the structure of substrate and inhibitor interaction sites.

1 February 2008 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MWMollie H Wright
Mollie H Wright
ACAnna Maria Calcagno
Anna Maria Calcagno
CSCrystal D Salcido
Crystal D Salcido
MCMarisa D Carlson
Marisa D Carlson
SASuresh V Ambudkar
Suresh V Ambudkar
LVLyuba Varticovski
Lyuba Varticovski
Introduction: Whether cancer stem cells occur in BRCA1-associated breast cancer and contribute to therapeutic response is not known. Methods: We generated and characterized 16 cell lines from five distinct Brca1deficient mouse mammary tumors with respect to their cancer stem cell characteristics. Results: All cell lines derived from one tumor included increased numbers of CD44+/CD24- cells, which were previously identified as human breast cancer stem cells. All cell lines derived from another mammary tumor exhibited low levels of CD44+/CD24- cells, but they harbored 2% to 5.9% CD133+ cells, which were previously associated with cancer stem cells in other human and murine tumors. When plated in the absence of attachment without presorting, only those cell lines that were enriched in either stem cell marker formed spheroids, which were further enriched in cells expressing the respective cancer stem cell marker. In contrast, cells sorted for CD44+/CD24- or CD133+ markers lost their stem cell phenotype when cultured in monolayers. As few as 50 to 100 CD44+/CD24- or CD133+ sorted cells rapidly formed tumors in nonobese diabetic/severe combined immunodeficient mice, whereas 50-fold to 100-fold higher numbers of parental or stem cell depleted cells were required to form few, slow-growing tumors. Expression of stem cell associated genes, including Oct4, Notch1, Aldh1, Fgfr1, and Sox1, was increased in CD44+/CD24- and CD133+ cells. In addition, cells sorted for cancer stem cell markers and spheroid-forming cells were significantly more resistant to DNA-damaging drugs than were parental or stem cell depleted populations, and they were sensitized to the drugs by the heat shock protein-90 inhibitor 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride). Conclusion: Brca1-deficient mouse mammary tumors harbor heterogeneous cancer stem cell populations, and CD44+/CD24- cells represent a population that correlates with human breast cancer stem cells.

8 November 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JGJean-Pierre Gillet
Jean-Pierre Gillet
ACAnna Maria Calcagno
Anna Maria Calcagno
SVSudhir Varma
Sudhir Varma
MMMiguel Marino
Miguel Marino
LGLisa J. Green
Lisa J. Green
MGMichael Gottesman
Michael Gottesman
Although in vitro models have been a cornerstone of anti-cancer drug development, their direct applicability to clinical cancer research has been uncertain. Using a state-of-the-art Taqman-based quantitative RT-PCR assay, we investigated the multidrug resistance (MDR) transcriptome of six cancer types, in established cancer cell lines (grown in monolayer, 3D scaffold, or in xenograft) and clinical samples, either containing >75% tumor cells or microdissected. The MDR transcriptome was determined a priori based on an extensive curation of the literature published during the last three decades, which led to the enumeration of 380 genes. No correlation was found between clinical samples and established cancer cell lines. As expected, we found up-regulation of genes that would facilitate survival across all cultured cancer cell lines evaluated. More troubling, however, were data showing that all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model. Although cultured cells can be used to study many aspects of cancer biology and response of cells to drugs, this study emphasizes the necessity for new in vitro cancer models and the use of primary tumor models in which gene expression can be manipulated and small molecules tested in a setting that more closely mimics the in vivo cancer microenvironment so as to avoid radical changes in gene expression profiles brought on by extended periods of cell culture.

3 November 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
ACAnna Maria Calcagno
Anna Maria Calcagno
CSCrystal D. Salcido
Crystal D. Salcido
JGJean-Pierre Gillet
Jean-Pierre Gillet
CWChung-Pu Wu
Chung-Pu Wu
JFJennifer M. Fostel
Jennifer M. Fostel
SASuresh Ambudkar
Suresh Ambudkar
Cancer stem cells are presumed to have virtually unlimited proliferative and self-renewal abilities and to be highly resistant to chemotherapy, a feature that is associated with overexpression of ATP-binding cassette transporters. We investigated whether prolonged continuous selection of cells for drug resistance enriches cultures for cancer stem–like cells. Cancer stem cells were defined as CD44+/CD24− cells that could self-renew (ie, generate cells with the tumorigenic CD44+/CD24− phenotype), differentiate, invade, and form tumors in vivo. We used doxorubicin-selected MCF-7/ADR cells, weakly tumorigenic parental MCF-7 cells, and MCF-7/MDR, an MCF-7 subline with forced expression of ABCB1 protein. Cells were examined for cell surface markers and side-population fractions by microarray and flow cytometry, with in vitro invasion assays, and for ability to form mammospheres. Xenograft tumors were generated in mice to examine tumorigenicity (n = 52). The mRNA expression of multidrug resistance genes was examined in putative cancer stem cells and pathway analysis of statistically significantly differentially expressed genes was performed. All statistical tests were two-sided. Pathway analysis showed that MCF-7/ADR cells express mRNAs from ABCB1 and other genes also found in breast cancer stem cells (eg, CD44, TGFB1, and SNAI1). MCF-7/ADR cells were highly invasive, formed mammospheres, and were tumorigenic in mice. In contrast to parental MCF-7 cells, more than 30% of MCF-7/ADR cells had a CD44+/CD24− phenotype, could self-renew, and differentiate (ie, produce CD44+/CD24− and CD44+/CD24+ cells) and overexpressed various multidrug resistance–linked genes (including ABCB1, CCNE1, and MMP9). MCF-7/ADR cells were statistically significantly more invasive in Matrigel than parental MCF-7 cells (MCF-7 cells = 0.82 cell per field and MCF-7/ADR = 7.51 cells per field, difference = 6.69 cells per field, 95% confidence interval = 4.82 to 8.55 cells per field, P < .001). No enrichment in the CD44+/CD24− or CD133+ population was detected in MCF-7/MDR. The cell population with cancer stem cell characteristics increased after prolonged continuous selection for doxorubicin resistance.

16 July 2018 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Open access
PDF file
LHLisa A. Hechtman
Lisa A. Hechtman
NMNathan P. Moore
Nathan P. Moore
CSClaire E. Schulkey
Claire E. Schulkey
AMAndrew C. Miklos
Andrew C. Miklos
ACAnna Maria Calcagno
Anna Maria Calcagno
JGJudith H. Greenberg
Judith H. Greenberg
Women have achieved parity with men among biomedical science degree holders but remain underrepresented in academic positions. The National Institutes of Health (NIH)—the world’s largest public funder of biomedical research—receives less than one-third of its new grant applications from women. Correspondingly, women compose less than one-third of NIH research grantees, even though they are as successful as men in obtaining first-time grants. Our study examined women’s and men’s NIH funding trajectories over time (n = 34,770), exploring whether women remain funded at the same rate as men after receiving their first major research grants. A survival analysis demonstrated a slightly lower funding longevity for women. We next examined gender differences in application, review, and funding outcomes. Women individually held fewer grants, submitted fewer applications, and were less successful in renewing grants—factors that could lead to gender differences in funding longevity. Finally, two adjusted survival models that account for initial investigator characteristics or subsequent application behavior showed no gender differences, suggesting that the small observed longevity differences are affected by both sets of factors. Overall, given men’s and women’s generally comparable funding longevities, the data contradict the common assumption that women experience accelerated attrition compared with men across all career stages. Women’s likelihood of sustaining NIH funding may be better than commonly perceived. This suggests a need to explore women’s underrepresentation among initial NIH grantees, as well as their lower rates of new and renewal application submissions. Significance Diversity of the biomedical workforce is essential to the scientific enterprise, yet women remain underrepresented in academic positions in biomedical sciences and compose less than one-third of National Institutes of Health (NIH) research grantees. We explored NIH grant support as a proxy for participation in academic research. We found that women had similar funding longevity as men after they received their first major NIH grants, contradicting the common assumption that across all career stages, women experience accelerated attrition compared with men. Despite longevity similarities, women composed only 31% of grantees in our analysis. This discrepancy in grantee demographics suggests that efforts may be best directed toward encouraging women to enter academia and supporting their continued grant submissions.

1 September 2005 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
CWChung‐Pu Wu
Chung‐Pu Wu
ACAnna Maria Calcagno
Anna Maria Calcagno
SHStephen B. Hladky
Stephen B. Hladky
SASuresh Ambudkar
Suresh Ambudkar
MBMargery A. Barrand
Margery A. Barrand
Plant flavonoids are polyphenolic compounds, commonly found in vegetables, fruits and many food sources that form a significant portion of our diet. These compounds have been shown to interact with several ATP‐binding cassette transporters that are linked with anticancer and antiviral drug resistance and, as such, may be beneficial in modulating drug resistance. This study investigates the interactions of six common polyphenols; quercetin, silymarin, resveratrol, naringenin, daidzein and hesperetin with the multidrug‐resistance‐associated proteins, MRP1, MRP4 and MRP5. At nontoxic concentrations, several of the polyphenols were able to modulate MRP1‐, MRP4‐ and MRP5‐mediated drug resistance, though to varying extents. The polyphenols also reversed resistance to NSC251820, a compound that appears to be a good substrate for MRP4, as predicted by data‐mining studies. Furthermore, most of the polyphenols showed direct inhibition of MRP1‐mediated [3H]dinitrophenyl S‐glutathione and MRP4‐mediated [3H]cGMP transport in inside‐out vesicles prepared from human erythrocytes. Also, both quercetin and silymarin were found to inhibit MRP1‐, MRP4‐ and MRP5‐mediated transport from intact cells with high affinity. They also had significant effects on the ATPase activity of MRP1 and MRP4 without having any effect on [32P]8‐azidoATP[αP] binding to these proteins. This suggests that these flavonoids most likely interact at the transporter's substrate‐binding sites. Collectively, these results suggest that dietary flavonoids such as quercetin and silymarin can modulate transport activities of MRP1, ‐4 and ‐5. Such interactions could influence bioavailability of anticancer and antiviral drugs in vivo and thus, should be considered for increasing efficacy in drug therapies.